Skip to content
Screener

BridgeBio Pharma BBIO Treasury Stock

Treasury Stock at other companies

Pfizer logo
PfizerPFE
$115.19B+0.2%
Royalty Pharma logo
Royalty PharmaRPRX
$2.72M+4.3%
Arrowhead Research logo
Arrowhead ResearchARWR
$53.19M
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$10M+25.1%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$10.98M0.0%

Other financials

Income statement

See full
Revenue$243.7M+120%
Gross profit$228.6M+114%
Operating income-$107.1M+20.3%
Net income-$155.9M+15.2%
EPS (diluted)-$0.78+17.9%

Balance sheet

See full
Cash & equivalents$680.0M-9.5%
Total debt$3.3B+36,912%
Total equity-$2.5B-40.7%
Total assets$1.2B+12.7%

Cash flow

See full
Operating cash flow-$71.1M+11.9%
CapEx$443.0K-25.4%
Free cash flow-$71.5M+12.0%

Valuation

See full
Market cap$16.55B+79.4%
Enterprise value$19.13B+126%
P/S23.2×-15.9×

Profitability

See full
Gross margin94.4%-1.8pp
Operating margin-69.8%-29.9pp
Net margin-98.5%-40.7pp
FCF margin-61.1%-26.8pp

Returns & leverage

See full
Return on equity-216.8%
Debt / equity
Current ratio1.2×-4.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:TreasuryStockCommonValue.

The source filing: BridgeBio Pharma’s 10-Q, filed August 10, 2026.

Filed
Aug 10, 2026, 4:31 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001743881-26-000027
Line itemJune 30,2026December 31,2025
Stockholders’ deficit:
Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 500,000,000 shares authorized; 205,867,350 shares issued and 195,284,352 shares outstanding as of June 30, 2026; 202,369,129 shares issued and 194,771,957 shares outstanding as of December 31, 2025206202
Treasury stock, at cost; 10,582,998 shares as of June 30, 2026; 7,597,172 shares as of December 31, 2025(533,279)(323,276)
Additional paid-in capital2,155,3182,057,646
Accumulated other comprehensive income (loss)(7)12
Accumulated deficit(4,137,453)(3,821,194)
Total BridgeBio stockholders’ deficit(2,515,215)(2,086,610)

Item 1. Financial Statements (Unaudited)

FAQ

What is BridgeBio Pharma's treasury stock?
BridgeBio Pharma (BBIO) reported treasury stock of $533.28M in Q2 2026.
How has BridgeBio Pharma's treasury stock changed year-over-year?
BridgeBio Pharma's treasury stock increased by 65.0% year-over-year, from $323.28M to $533.28M.
What is the long-term trend for BridgeBio Pharma's treasury stock?
Over 5 years (2020 to 2025), BridgeBio Pharma's treasury stock has grown at a 33.9% compound annual growth rate (CAGR), from $75M to $323.28M.
What does treasury stock mean?
Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.

Ask your AI about BridgeBio Pharma's treasury stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude